Effective date: 4 June 2026
MindImmune Therapeutics ("MindImmune," "we," "us," or "our") is a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative disease. This Privacy Policy explains how we collect, use, and protect information when you visit our website (the "Site"). The Site is informational and is not intended for the submission of personal health information or for patient or clinical-trial recruitment.
We collect two categories of information. Information you provide: when you submit our contact form we collect your name, email address, and the contents of your message; when you sign up for our newsletter we collect your email address. Information collected automatically: when you browse the Site we may collect device and browser type, IP address, referring pages, and usage activity through cookies and similar technologies.
We use the information we collect to respond to your inquiries and communicate with you; to send company updates and news about our pipeline, including our lead candidate MITI-101, where you have asked to receive them; to operate, maintain, secure, and improve the Site; and to comply with legal obligations and protect our rights.
We use cookies and analytics tools to understand how visitors use the Site and to improve its performance. You can control cookies through your browser settings; disabling them may affect how the Site functions.
We do not sell your personal information. We may share information with service providers who help us operate the Site and our communications, such as our website hosting platform, analytics providers, and email service providers; with legal or safety recipients where required by law or to protect our rights; and with successors in connection with a merger, financing, acquisition, or other corporate transaction.
We retain personal information for as long as needed to fulfill the purposes described in this Policy, unless a longer retention period is required or permitted by law.
We use reasonable administrative, technical, and organizational measures to protect personal information. No method of transmission or storage is completely secure, however, and we cannot guarantee absolute security.
Depending on your location, you may have the right to access, correct, delete, or restrict the use of your personal information, or to object to certain processing. You can unsubscribe from our newsletter at any time using the link in our emails. To exercise any of these rights, contact us using the details below.
MindImmune is based in the United States. If you access the Site from outside the United States, you understand that your information may be transferred to and processed in the United States, where data protection laws may differ from those in your country.
The Site is not directed to children under the age of 16, and we do not knowingly collect personal information from children. If you believe a child has provided us with personal information, please contact us so we can delete it.
Information on the Site about neurodegenerative disease, our research, and investigational candidates such as MITI-101 is provided for general informational purposes only. It is not medical advice, and no investigational product described on the Site has been approved as safe or effective by any regulatory authority. Contacting us does not create a clinician-patient relationship.
We may update this Privacy Policy from time to time. We will post the updated version on this page and revise the effective date above.
If you have questions about this Privacy Policy or our data practices, contact us.
This Privacy Policy is provided as a general template and does not constitute legal advice. Please have it reviewed by qualified legal counsel before publishing.